ImmuCell Earnings Call Transcripts
Fiscal Year 2026
-
Second quarter 2026 saw 11.5% sales growth and strong domestic performance, offset by lower international sales. Gross margin declined due to cost shifts and lower output, but net income and adjusted EBITDA rose sharply, aided by a $2M legal settlement.
-
The meeting confirmed a quorum and approved all proposals, including director elections, executive compensation, a new stock plan, a charter amendment, and auditor ratification. A major two-phase manufacturing expansion was announced to support sustained product demand and growth.
-
Record Q1 2026 revenue and net income growth driven by strong Tri-Shield sales, margin expansion, and increased U.S. market share. Capacity and sales force investments support continued growth, with international expansion and plant upgrades underway.
Fiscal Year 2025
-
2025 saw 4.3% sales growth to $27.6M, gross margin rise to 41%, and a $3.3M operating income swing, driven by expanded capacity and a strategic focus on First Defense. Net loss narrowed to $1M despite significant non-cash write-downs.
-
Strategic focus shifted to First Defense, driving strong domestic sales and operational gains, while Re-Tain investment is paused due to regulatory setbacks. Q4 2025 saw near-record sales, with Tri-Shield growth and asset repurposing supporting future expansion.
-
Reported a strong financial turnaround with net income of $1.8 million and gross margin rising to 43% for the nine months ended September 30, 2025. Domestic sales showed positive momentum, and new leadership is focused on operational excellence and growth initiatives.
-
Focused on antibody-based products for calf health, the company has doubled manufacturing capacity and achieved strong financial growth in early 2025. Re-Tain, a new non-antibiotic mastitis treatment, is in late-stage FDA review, and leadership transition is planned for year-end.
-
Q2 2025 saw strong sales and margin growth, driven by restored First Defense supply and inventory rebuild, though a temporary sales boost is expected to normalize in H2. Re-Tain's commercial launch remains delayed pending FDA approval, with all expiring inventory used for investigational studies.
-
Production capacity has doubled, driving strong sales and margin recovery after past disruptions. First Defense now offers broader pathogen coverage and immediate immunity, while Re-Tain is set for investigational use in 2025 as FDA approval is pending.
-
Record Q1 2025 sales and gross margin expansion reflect operational recovery and strong demand for the First Defense suite. Production capacity upgrades and backlog reduction position the business for continued growth, while investigational use of Re-Tain advances product development.
-
Key milestones are expected in 2025, with First Defense expanding its market presence and Re-Tain nearing FDA approval. Manufacturing challenges have been overcome, and new product formats aim to capture more market share while reducing antibiotic use.
Fiscal Year 2024
-
Sales grew 52% year-over-year in Q4 and 2024, with gross margin and EBITDA rebounding sharply after resolving production issues. Awaiting FDA approval for Re-Tain, while new product formats and increased capacity position the company for further growth.
-
Sales rose sharply year-over-year, driven by strong demand for First Defense, while gross margin improved but remains below target due to higher costs and product mix. Remediation of production issues and an ATM offering strengthened operations and cash position.
-
Strong sales growth and improved production capacity drove higher output, but gross margin remains below target due to past contamination and yield issues. Operational improvements and yield initiatives are underway, with regulatory progress for Re-Tain ongoing.